ALVO: Pending FDA approvals and strong biosimilar launches drive growth, with robust financial outlook

Multiple BLAs are pending FDA approval, with positive inspection outcomes and launches expected by year-end. Direct U.S. commercialization is expanding for select products, while European biosimilar launches show strong uptake. Financial guidance is supported by robust manufacturing and recent capi…